Form 4: Supernus Pharmaceuticals Director Acquires Shares Through Restricted Stock Unit Vesting

Director Frederick M. Hudson acquired 5,369 shares of Supernus Pharmaceuticals common stock through the vesting of restricted stock units on February 22, 2025.

Summary

• On February 22, 2025, Frederick M. Hudson, a director of Supernus Pharmaceuticals, acquired 5,369 shares of common stock.
• The acquisition resulted from the vesting and settlement of restricted stock units (RSUs).
• Each RSU represents the right to receive one share of Supernus common stock upon vesting.
• The RSUs were settled in common stock upon vesting, which occurred on February 22, 2025.
• Following the transaction, Hudson directly owns 53,764 shares of Supernus Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The transaction itself is routine, but increased insider ownership can be viewed favorably.

Positives

• The vesting of RSUs indicates that the director is incentivized and aligned with the company's performance.
• Increased share ownership by a director can be seen as a positive sign by investors.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely monitored by investors to gauge sentiment and potential future actions by key individuals within the company.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders due to increased insider ownership.

Key Dates

Keywords

Supernus Pharmaceuticals, Director, Frederick M. Hudson, Stock Acquisition, Restricted Stock Units, RSU, Beneficial Ownership, Form 4, SUPN